In addition to Kyprolis, Amgen’s other oncology drugs Xgeva, Nplate, and Neulasta also displayed strong revenue growth in 3Q15. Biogen (BIIB), Gilead Sciences (GILD), and Amgen (AMGN) are also actively involved in strengthening their position in the $100 billion oncology market. To know more about Amgen’s oncology segment, please read Amgen: Focusing on the Oncology Segment.
Neulasta and Neupogen
In 3Q15, Neulasta’s revenues were about $1.3 billion, 6% higher than revenues earned by the drug in 3Q14. The rise was mainly driven by changes in the drug’s net selling price, a combination of changes in list price and access provided by the health insurers to the drug. Neulasta also benefitted from high purchases from large customers in 3Q15. Neulasta’s on-body injector, branded as part of the Neulasta Onpro kit, has further helped to ease the delivery of the drug. The Onpro kit is used by 19% of Neulasta’s total patient volume.
Unlike Neulasta, Neupogen suffered from a 5% year-over-year fall in revenues in 3Q15, due to increasing competition in the market. With Novartis (NVS) launching the first biosimilar version Zarxio for Neupogen on September 03, 2015, Neupogen’s sales are expected to fall in future quarters.
Xgeva registered a YoY revenue growth of 19%, from $318 million in 3Q14 to $378 million in 3Q15, driven mainly by a rise in market share in both the United States and Europe. Market share rose due to the drug’s superior clinical profile as compared to its peers, as well as abnormally high purchases by certain customers. To know more about Xgeva, please refer to Xgeva: Focusing on Skeletal-Related Events in Cancer Patients.
Nplate and Vectibix
In 3Q15, Nplate’s revenues reached $137 million, a 15% rise from the $119 million earned in 3Q14. This growth was driven by a rise in demand. Vectibix, however, witnessed a YoY fall of 4% in total revenues, from $138 million in 3Q14 to $132 million in 3Q15.
Amgen accounts for 4.4% of the Health Care Select Sector SPDR Fund’s (XLV) total holdings.